A detailed history of Black Rock Inc. transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Black Rock Inc. holds 124,672 shares of HOOK stock, worth $268,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124,672
Previous 289,293 56.9%
Holding current value
$268,044
Previous $205,000 64.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.59 - $1.04 $97,126 - $171,205
-164,621 Reduced 56.9%
124,672 $73,000
Q1 2024

May 10, 2024

SELL
$0.61 - $0.83 $3,037 - $4,132
-4,979 Reduced 1.69%
289,293 $205,000
Q4 2023

Feb 13, 2024

SELL
$0.42 - $0.86 $406 - $832
-968 Reduced 0.33%
294,272 $238,000
Q3 2023

Nov 13, 2023

BUY
$0.58 - $0.91 $21,936 - $34,418
37,822 Added 14.69%
295,240 $183,000
Q2 2023

Aug 11, 2023

SELL
$0.71 - $1.97 $57,691 - $160,074
-81,256 Reduced 23.99%
257,418 $226,000
Q1 2023

May 12, 2023

BUY
$0.72 - $1.03 $2,582 - $3,694
3,587 Added 1.07%
338,674 $250,000
Q4 2022

Feb 13, 2023

BUY
$0.73 - $14.6 $1,681 - $33,623
2,303 Added 0.69%
335,087 $271,000
Q3 2022

Nov 14, 2022

BUY
$1.27 - $15.0 $5,060 - $59,775
3,985 Added 1.21%
332,784 $445,000
Q2 2022

Aug 12, 2022

SELL
$1.33 - $2.31 $1.1 Million - $1.92 Million
-830,373 Reduced 71.64%
328,799 $537,000
Q1 2022

May 12, 2022

SELL
$1.26 - $2.52 $67,195 - $134,391
-53,330 Reduced 4.4%
1,159,172 $2.64 Million
Q4 2021

Feb 10, 2022

BUY
$2.33 - $5.94 $370,442 - $944,388
158,988 Added 15.09%
1,212,502 $2.83 Million
Q3 2021

Nov 09, 2021

BUY
$5.89 - $9.35 $17,628 - $27,984
2,993 Added 0.28%
1,053,514 $6.2 Million
Q2 2021

Aug 11, 2021

BUY
$9.16 - $19.51 $9.62 Million - $20.5 Million
1,050,521 New
1,050,521 $9.62 Million

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $111M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.